Supportive care of women with breast cancer: Key concerns and practical solutions

Medical Journal of Australia

Volumn 205, Issue 10, 2016, Pages 471-475

  Zdenkowski, Nicholas ^a   Tesson, Stephanie ^b   Lombard, Janine ^a,c   Lovell, Melanie ^d   Hayes, Sandra ^e   Francis, Prudence A ^f,g   Dhillon, Haryana M ^b   Boyle, Frances M ^b,c  

^a CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF NEWCASTLE   (Australia)

^d Palliative Care and Supportive Care Service   (Australia)

^e QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^f PETER MACCALLUM CANCER CENTRE   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; OPIATE; ANTIESTROGEN; TAMOXIFEN;

ALOPECIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; COGNITIVE DEFECT; COGNITIVE REHABILITATION; COOLING; EXERCISE; FEAR; FEMALE; HUMAN; MUSCULOSKELETAL DISEASE; PAIN; PATIENT CARE; PSYCHOSOCIAL CARE; REVIEW; SELF CARE; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SEXUALITY; SUPPORTIVE CARE; ANALGESIA; BREAST NEOPLASMS; FATIGUE; PSYCHOLOGY; PSYCHOSEXUAL DISORDER; QUALITY OF LIFE;

ALOPECIA; AROMATASE INHIBITORS; BREAST NEOPLASMS; COGNITIVE DYSFUNCTION; ESTROGEN ANTAGONISTS; EXERCISE; FATIGUE; FEAR; FEMALE; HUMANS; PAIN; PAIN MANAGEMENT; QUALITY OF LIFE; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; TAMOXIFEN;

EID: 85016923706     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/MJA16.00947     Document Type: Review

References (50)

1. Australian Institute of Health and Welfare. Australian Cancer Incidence and Mortality (ACIM) books: breast cancer. Canberra: AIHW, 2016.
2. Kemp-Casey A, Roughead ER, Saunders C, et al. Breast cancer recurrence following active treatment: determining its incidence in the NSW population. Public Health Res Pract 2016; 26: e2611607.
3. Hodgkinson K, Butow P, Hunt GE, et al. Breast cancer survivors’ supportive care needs 2e10 years after diagnosis. Support Care Cancer 2007; 15: 515-523.
4. Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014; 371: 107-118.
5. Francis PA, Regan MM, Fleming GF, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 2015; 372: 436-446.
6. Moore HCF, Unger JM, Phillips K-A, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 2015; 372: 923-932.
7. Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 2016; 375: 209-219.
8. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007; 25: 820-828.
9. Daley A, Stokes-Lampard H, Thomas A, MacArthur C. Exercise for vasomotor menopausal symptoms. Cochrane Database Syst Rev 2014; (11): CD006108.
10. The North American Menopause Society. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause 2015; 22: 1155-1172.
11. Singh MS, Francis PA, Michael M. Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes. Breast 2011; 20: 111-118.
12. Vitry AI, Thai LP, Lu CY. Time and geographical variations in utilization of endocrine therapy for breast cancer in Australia. Intern Med J 2011; 41: 162-166.
13. Burstein HJ. Aromatase inhibitor-associated arthralgia syndrome. Breast 2007; 16: 223-234.
14. Lintermans A, Van Calster B, Van Hoydonck M, et al. Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis. Ann Oncol 2011; 22: 1763-1769.
15. Lombard JM, Zdenkowski N, Wells K, et al. Aromatase inhibitor induced musculoskeletal syndrome: a significant problem with limited treatment options. Support Care Cancer 2015; 24: 2139-2146.
16. Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 2011; 126: 529-537.
17. Coleman RE, Bolten WW, Lansdown M, et al. Aromatase inhibitor-induced arthralgia: Clinical experience and treatment recommendations. Cancer Treat Rev 2008; 34: 275-282.
18. Hashem MG, Cleary K, Fishman D, et al. Effect of concurrent prescription antiarthralgia pharmacotherapy on persistence to aromatase inhibitors in treatmentnaive postmenopausal females. Ann Pharmacother 2013; 47: 29-34.
19. Irwin ML, Cartmel B, Gross CP, et al. Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol 2015; 33: 1104-1114.
20. Briot K, Tubiana-Hulin M, Bastit L, et al. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast Cancer Res Treat 2010; 120: 127-134.
21. Candy B, Jones L, Vickerstaff V, et al. Interventions for sexual dysfunction following treatments for cancer in women. Cochrane Database Syst Rev 2016; (2): CD005540.
22. Ussher JM, Perz J, Gilbert E. Perceived causes and consequences of sexual changes after cancer for women and men: a mixed method study. BMC Cancer 2015; 15: 268-286.
23. Goetsch MF, Lim JY, Caughey AB. A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial. J Clin Oncol 2015; 33: 3394-3400.
24. Farrell R. ACOG Committee Opinion No. 659: The use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstet Gynecol 2016; 127: e93-e96.
25. Lawsin C, McGeechan K, Beaumont A, et al. Rekindle update: Rekindle is demonstrating broad reach across Australia in providing psychosexual support to both cancer survivors and their partners [abstract]. Asia Pac J Clin Oncol 2015; S4: 105-182.
26. van den Hurk CJ, Mols F, Vingerhoets AJ, Breed WP. Impact of alopecia and scalp cooling on the well-being of breast cancer patients. Psychooncology 2010; 19: 701-709.
27. Kluger N, Jacot W, Frouin E, et al. Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients. Ann Oncol 2012; 23: 2879-2884.
28. van den Hurk CJ, Peerbooms M, van de Poll-Franse LV, et al. Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients - results of the Dutch Scalp Cooling Registry. Acta Oncol 2012; 51: 497-504.
29. Lemieux J, Provencher L, Perron L, et al. No effect of scalp cooling on survival among women with breast cancer. Breast Cancer Res Treat 2015; 149: 263-268.
30. Vickberg SM, Johnson P. The concerns about recurrence scale (CARS): a systematic measure of women’s fears about the possibility of breast cancer recurrence. Ann Behav Med 2003; 25: 16-24.
31. Simard S, Thewes B, Humphris G, et al. Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies. J Cancer Surviv 2013; 7: 300-322.
32. Crist JV, Grunfeld EA. Factors reported to influence fear of recurrence in cancer patients: a systematic review. Psychooncology 2013; 22: 978-986.
33. Thewes B, Butow P, Bell ML, et al. Fear of cancer recurrence in young women with a history of early-stage breast cancer: a cross-sectional study of prevalence and association with health behaviours. Support Care Cancer 2012; 20: 2651-2659.
34. Cancer Australia. Recommendations for the identification and management of fear of cancer recurrence in adult cancer survivors, June 2014. https://guidelines.canceraustralia.gov.au/guidelines/fear_of_recurrence/ch01.php (accessed July 2016).
35. Thewes B, Butow P, Zachariae R, et al. Fear of cancer recurrence: a systematic literature review of self-report measures. Psychooncology 2012; 21: 571-587.
36. Lebel S, Ozakinci G, Humphris G, et al. From normal response to clinical problem: definition and clinical features of fear of cancer recurrence. Support Care Cancer 2016; 24: 3265-3268.
37. Simonelli LE, Siegel SD, Duffy NM. Fear of cancer recurrence: a theoretical review and its relevance for clinical presentation and management. Psychooncology 2016; doi: 10.1002/pon.4168 [Epub ahead of print].
38. Butow PN, Bell ML, Smith AB, et al. Conquer fear: protocol of a randomised controlled trial of a psychological intervention to reduce fear of cancer recurrence. BMC Cancer 2013; 13: 201-211.
39. Deandrea S, Montanari M, Moja L, Apolone G. Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol 2008; 19: 1985-1991.
40. Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology breast cancer survivorship care guideline. J Clin Oncol 2015; 34: 611-635.
41. Glare PA, Davies PS, Finlay E, et al. Pain in cancer survivors. J Clin Oncol 2014; 32: 1739-1747.
42. Lovell MR, Luckett T, Boyle FM, et al. Patient education, coaching, and self-management for cancer pain. J Clin Oncol 2014; 32: 1712-1720.
43. Hui D, Bruera E. A personalized approach to assessing and managing pain in patients with cancer. J Clin Oncol 2014; 32: 1640-1646.
44. Wefel JS, Schagen SB. Chemotherapy-related cognitive dysfunction. Curr Neurol Neurosci Rep 2012; 12: 267-275.
45. Bray VJ, Dhillon HM, Bell M, et al. Evaluation of a webbased cognitive rehabilitation programme (CRP) in cancer survivors reporting cognitive symptoms following chemotherapy. J Clin Oncol 2015; 33 suppl; abstr 9510.
46. Hayes SC, Spence RR, Galvao DA, et al. Australian Association for Exercise and Sport Science position stand: optimising cancer outcomes through exercise. J Sci Med Sport 2009; 12: 428-434.
47. Ibrahim E, Al-Homaidh A. Physical activity and survival after breast cancer diagnosis: meta-analysis of published studies. Med Oncol 2011; 28: 753-765.
48. Harrison S, Hayes SC, Newman B. Level of physical activity and characteristics associated with change following breast cancer diagnosis and treatment. Psychooncology 2009; 18: 387-394.
49. Rock CL, Doyle C, Demark-Wahnefried W, et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin 2012; 62: 227-242.
50. White SM, McAuley E, Estabrooks PA, Courneya KS. Translating physical activity interventions for breast cancer survivors into practice: an evaluation of randomized controlled trials. Ann Behav Med 2009; 37: 10-19.